AstraZeneca's Fasenra failed to reduce flare-ups in COPD patients in a late-stage trial, a setback for the company's efforts to address the severe lung disease. Despite this, AstraZeneca will analyze the data to understand the results better, while its rare disease drug Saphnelo succeeded in a lupus trial.